Analyst Price Targets — OTLK
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| July 27, 2026 4:06 pm | Douglas Tsao | H.C. Wainwright | $1.60 | $1.08 | TheFly | Outlook Therapeutics price target raised to $1.60 from 50c at H.C. Wainwright |
| July 27, 2026 10:12 am | — | BTIG | $4.00 | $1.41 | TheFly | Outlook Therapeutics upgraded to Buy from Neutral at BTIG |
| January 2, 2026 11:13 pm | Daniil Gataulin | Chardan Capital | $1.00 | $0.66 | TheFly | Outlook Therapeutics price target lowered to $1 from $3 at Chardan |
| August 29, 2025 10:46 am | Douglas Tsao | H.C. Wainwright | $1.00 | $1.09 | TheFly | Outlook Therapeutics downgraded at H.C. Wainwright |
Latest News for OTLK
Fireside chat featuring Bob Jahr, Chief Executive Officer, and H.C. Wainwright Managing Director & Senior Biotechnology Equity Research Analyst
Seasoned finance executive brings more than 20 years of leadership experience across global commercial organizations, including the pharmaceutical and medical technology industries Deep expertise spans commercial operations, capital markets, public company finance, and building scalable financial and operational infrastructure
Video webcast now available here
Outlook Therapeutics targets a year-end 2026 U.S. LYTENAVA launch, with $50M-$75M in first-year net revenues and a ramp tied to reimbursement.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for OTLK.
U.S. House Trading
No House trades found for OTLK.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.